Antibody drug candidates with promising biochemical and biophysical properties can be selected at early stage of drug development. At LakePharma, a series of fast and small-scale tests, as well as in silico predictive tools are employed to serve as an additional selection criteria for better and safer therapeutic leads.
-CE-SDS (Reducing and non-reducing)
-DSF / DLS
-Octet (FcRn and Fc-gamma R binding profile)
-Sequence liability analysis
-Forced degradation study
Please contact LakePharma at firstname.lastname@example.org for custom quotes and details.